Compare WLFC & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLFC | STOK |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 1997 | 2019 |
| Metric | WLFC | STOK |
|---|---|---|
| Price | $56.46 | $32.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $160.00 | $39.20 |
| AVG Volume (30 Days) | 159.6K | ★ 610.8K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ 2.39 | N/A |
| Revenue | ★ $569,223,000.00 | $184,420,000.00 |
| Revenue This Year | $2.75 | N/A |
| Revenue Next Year | $7.35 | $77.49 |
| P/E Ratio | $25.54 | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $60.22 | $13.04 |
| 52 Week High | $244.62 | $40.22 |
| Indicator | WLFC | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 15.53 | 58.98 |
| Support Level | N/A | $30.34 |
| Resistance Level | $74.22 | $34.83 |
| Average True Range (ATR) | 3.56 | 1.54 |
| MACD | -0.28 | 0.40 |
| Stochastic Oscillator | 0.14 | 81.09 |
Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum Lease rent revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.